Purpose: To evaluate the effect of intra-vitreal bevacizumab in macular edema
caused by branch retinal vein occlusion.
Study Design: Interrupted time series study.
Place and Duration of Study: Department of Ophthalmology Hayatabad
Medical Complex, Peshawar and department of Ophthalmology Lady Reading
Hospital Peshawar from 1st July 2016 to 31st December 2016.
Material and Methods: There were 60 patients included in the study. All
patients with macular edema due to BRVO visible clinically and evident on SDOCT and visual acuity of less than 6/9 were included in the study. Patients who
used other intra-vitreal drug for macular edema, those with surgery in the same
eye and those with macular laser for macular edema were excluded from the
study. All patients were given intra-vitreal 0.05 ml bevacizumab injection every
month for 6 months. After 6 months OCT was repeated. At each monthly visit
VA was measured and fundoscopy was done. Follow up of all patients was at
six months.
Results: Our study included 60 patients with mean age of 54.42 ± 9.19 years.
The mean baseline central macular thickness was 427.06 µ with SD ± 63.54 µ.
After 6 months significant improvement in visual acuity was documented. Also
marked reduction in central macular thickness was noted after six months with
mean of 327.44 µ with SD ± 55.55 µ.
Conclusion: Intra-vitreal bevacizumab is an effective treatment for macular
edema caused by BRVO in terms of both anatomic and visual improvement
